Pulse Biosciences (NASDAQ:PLSE) COO Buys $49,993.90 in Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) COO Liane Rae Teplitsky purchased 1,034 shares of the company’s stock in a transaction dated Friday, August 28th. The shares were purchased at an average cost of $48.35 per share, for a total transaction of $49,993.90. Following the transaction, the chief operating officer directly owned 2,070 shares in the company, valued at approximately $100,084.50. This represents a 99.81% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Liane Rae Teplitsky also recently made the following trade(s):

• On Wednesday, August 26th, Liane Rae Teplitsky purchased 1,036 shares of Pulse Biosciences stock. The shares were purchased at an average price of $48.23 per share, for a total transaction of $49,966.28.

Pulse Biosciences Price Performance

PLSE stock opened at $47.57 on Monday. Pulse Biosciences, Inc has a 1-year low of $12.56 and a 1-year high of $50.90. The business has a 50-day moving average price of $35.38 and a 200 day moving average price of $27.02. The company has a market capitalization of $3.29 billion, a P/E ratio of -40.31 and a beta of 1.61.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The business had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $0.53 million. On average, analysts anticipate that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on PLSE. Wall Street Zen upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Canaccord Genuity Group lifted their target price on Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Oppenheimer reiterated an “outperform” rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Finally, Needham & Company LLC started coverage on shares of Pulse Biosciences in a research report on Monday, August 17th. They set a “buy” rating and a $58.00 price target for the company. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Pulse Biosciences has an average rating of “Moderate Buy” and a consensus target price of $45.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in PLSE. California State Teachers Retirement System increased its position in Pulse Biosciences by 2,600.0% during the 2nd quarter. California State Teachers Retirement System now owns 567,883 shares of the company’s stock valued at $15,747,000 after buying an additional 546,850 shares in the last quarter. Formula Growth Ltd. purchased a new stake in shares of Pulse Biosciences during the second quarter worth about $832,000. Panoramic Capital LLC purchased a new stake in shares of Pulse Biosciences during the second quarter worth about $2,719,000. Bank of America Corp DE acquired a new position in shares of Pulse Biosciences during the second quarter valued at about $40,115,000. Finally, Jupiter Topco LLC acquired a new position in shares of Pulse Biosciences during the second quarter valued at about $241,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.